profit from every $100 of sales.
$0$100
Unicycive Therapeutics
$3.55-2.47% today
-33.4% in 1 year
1-year low $3.361-year high $8.56
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Unicycive Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $951,000 in 2022 to $0 in 2025, with -$26.6 million of profit last year.
SalesProfit
Unicycive Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Unicycive Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Unicycive Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 1 | 0 | 0 | |
| – | – | – | – | |
| -18 | -21 | -32 | -30 | |
| -18 | -30 | -36 | -26 | |
| -18 | -31 | -37 | -27 | |
| -12.00 | -12.80 | -5.65 | -1.67 | |
| – | – | – | – | |
| -1,898.2% | -3,077.6% | – | – | |
| -1,898.8% | -4,525.0% | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 3 | 14 | 32 | 49 |
| Cash | 0 | 10 | 26 | 29 |
| Total debt | 0 | 1 | 1 | 0 |
| Total liabilities | 3 | 18 | 24 | 19 |
| -0 | -4 | 7 | 30 | |
| 2 | 2 | 7 | 16 | |
| – | – | -353.0% | -68.8% | |
| 3,875.1% | 801.9% | -494.3% | -87.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -18 | -29 | -31 | |
| 0 | 0 | 0 | 0 | |
| -16 | -18 | -29 | -31 | |
| Dividends paid | – | 0 | 1 | 0 |
| – | – | – | – | |
| 1 | 2 | 2 | 3 |
Valuation
- –
- –
- –
- 49.1×
- 144.1×
- –
- –
- -18.8%
- -31.4%
- 0.0%
Profitability
- 0.0%
- -3,077.6%
- -4,525.0%
- 0.0%
- -77.8%
- 1,447.7%
- -131.2%
- -62.0%
- -79.0%
- –
Growth
- −29.0%
- –
- −9.4%
- –
- +241.5%
Financial health
- -0.3×
- 0.02
- 1.3%
- -544.8×
- 2.40
- 2.40
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 952
Bottom 4%of 886
Bottom 4%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.54 | -0.46 | −17.7% |
| Mar 30, 2026 | -0.32 | -0.50 | +36.6% |
| Nov 12, 2025 | -0.39 | -0.59 | +33.9% |
| Aug 14, 2025 | -0.52 | -0.70 | +25.7% |
| Mar 31, 2025 | -0.26 | -0.13 | −100.0% |
| Mar 27, 2025 | -0.16 | -0.13 | −23.1% |
| Aug 14, 2024 | -0.15 | -0.23 | +34.8% |
| May 13, 2024 | -0.27 | -0.18 | −50.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
38No pass
Benjamin Graham
37No pass
Philip Fisher
40No pass
Peter Lynch
42No pass
Joel Greenblatt
2No pass
Charlie Munger
42No pass
Terry Smith
36No pass
Questions about Unicycive Therapeutics
Is Unicycive Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Unicycive Therapeutics AI analysis
What does Unicycive Therapeutics do?
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is in Biotechnology.
Does Unicycive Therapeutics pay a dividend?
No. Unicycive Therapeutics does not pay a dividend at the moment.
Is Unicycive Therapeutics stock halal?
Questionable. Unicycive Therapeutics sits in a grey zone: its cash and confirmed interest-bearing investments are 30% of its market value, between 30% and 33%. How we check
How has Unicycive Therapeutics stock done over the past year?
Down 33.4% over the past twelve months, to $3.55. It traded between $3.36 and $8.56 and is 58.5% below its high.
Who are Unicycive Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Unicycive Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.